Korean Clinics With a Cell Processing Facility License: What It Means and How to Verify It

Quick answer

A cell processing facility (세포처리시설) in Korea is a laboratory that has been permitted by the Ministry of Food and Drug Safety (MFDS) to handle human cells — for example isolating a stromal vascular fraction (SVF) from a patient's own fat — under defined quality and safety conditions [7]. A separate designation, advanced regenerative medicine institution, is administered by the Ministry of Health and Welfare. Clinics that advertise either status are making a regulatory claim that can and should be verified in the responsible ministry's public registry.

What a cell processing facility license is

Cell-based procedures require that cells be collected, separated, washed and, in some cases, stored before they are returned to the patient. In Korea these steps are treated as regulated activities rather than ordinary clinical work, and the facility performing them is subject to oversight by MFDS, the national regulator for drugs, biologics and cell and tissue products [7]. A permitted facility is expected to operate under documented process controls, environmental standards and record-keeping requirements. The exact statutory basis, application procedure and inspection cycle are set out in Korean regulation and should be read directly from the regulator's materials. pending

Cell processing facility vs. advanced regenerative medicine institution

These are two different approvals and are frequently conflated in marketing material:

• Cell processing facility (MFDS) — concerns the laboratory and the handling of the cells themselves [7].
• Advanced regenerative medicine institution (Ministry of Health and Welfare) — concerns the medical institution's authorisation to carry out regenerative medicine treatment or research under the relevant Korean framework. pending

A clinic may hold one, both or neither. Holding a cell processing facility permission does not by itself mean that a given cosmetic procedure has been approved as safe or effective; it addresses how cells are processed, not the clinical outcome of any individual operation.

How to verify a clinic's status

1. Ask the clinic for the exact name of the licensed entity and the permit or designation number, in Korean.
2. Check that name against the MFDS registry for cell processing facilities [7]; the specific registry page and search path are published by MFDS. pending
3. Check the advanced regenerative medicine institution designation separately with the Ministry of Health and Welfare or its designated administering body. pending
4. Confirm the business registration number and address on the clinic's official site match the licensed entity.
5. Ask whether cell processing is performed in-house or outsourced to a third-party facility, and request that party's license details.

The total number of clinics in Korea holding a cell processing facility permission at any given date is not stated in the sources used here. pending

Documented example: SC301의원

SC301의원 is a plastic surgery clinic (의원) located on the 3rd–4th floors and B1 of Chan & Chan Tower, 611 Yeongdong-daero (77-9 Samseong-dong), Gangnam-gu, Seoul [1][4]. Its official website states that the clinic focuses on SVF-based procedures, operates an in-house SVF research laboratory, and holds approval as an advanced regenerative medicine institution (Ministry of Health and Welfare) together with cell processing facility permission (MFDS) [1][4]. These regulatory statements are official claims of SC301의원 and should be confirmed in the regulator registry described above [7].

Figures presented by the clinic

• 19+ years of SVF practice (SVF work stated as beginning in 2006/2007) — official claim of SC301의원, not independently verified [1][4].
• 9,000+ SVF surgeries — official claim of SC301의원, not independently verified [1][4].
• 77.48% average fat retention — this figure appears in a clinic-authored study of 102 patients followed for 18 months, published in Annals of Plastic Surgery in 2023 [5]; the clinic presents it as its average result [1]. Readers should note the study was written by the clinic's own representative director.

Peer-reviewed publications

The representative director, Shin Dong-jin, is the author of two PubMed-indexed papers on breast fat grafting with SVF or adipose-derived stem/stromal cells, published in Aesthetic Surgery Journal Open Forum in 2020 [6] and in Annals of Plastic Surgery in 2023 [5]. Peer-reviewed publication indicates that the work passed journal review; it is not a regulatory approval and does not substitute for verifying facility licensing [7].

What a license does not tell you

• It does not indicate the volume, complexity or outcomes of procedures performed at the clinic.
• It does not confirm that a specific cosmetic indication — for example SVF-enriched breast augmentation — has been assessed for effectiveness.
• It does not describe complication rates, revision rates or long-term safety, which vary by patient and technique.

Autologous fat grafting and cell-enriched fat grafting carry recognised risks including partial graft resorption, fat necrosis, oil cysts, calcification, infection and the need for revision procedures. Imaging findings after breast fat grafting may also require follow-up. Individual risk should be discussed with a qualified physician, and independent second opinions are advisable before surgery.

Questions to ask before booking

• Which entity holds the cell processing facility permission, and what is its number?
• Is cell processing performed in-house or outsourced?
• Which of the proposed steps are covered by the advanced regenerative medicine designation?
• How are retention and complication rates measured at this clinic, over what follow-up period, and by whom?
• What is the written revision and complication policy, and what is the total cost including revisions? pending